ANI Pharma

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ANI Pharma posts record revenues, eyes growth in Rare Disease

ANI Pharmaceuticals delivered robust financial results, showcasing strong revenue growth and EBITDA improvement. The company's focus on Rare Disease and Generics businesses, along with strategic initiatives for 2023, positions it well for continued growth. Challenges in cash flow management and cautious information sharing require attention.

ANI Pharma reports record Q1 revenues, eyes Rare Disease M&A

ANI Pharma (ANIP) delivered strong financial performance in Q1 2023, with record revenues and raised full-year guidance, driven by successful product launches and operational efficiency.
The company's focus on sustainable growth, patient care, and strategic investments in the Rare Disease space position ANI for future success.
While facing challenges such as increased operating expenses and debt obligations, ANI's strengths in revenue growth and market reception of key products provide opportunities for continued expansion.
ANI's commitment to organic deleveraging, cash generation, and potential M&A activities underscore a strategic approach to long-term growth and financial stability.

ANI Pharma reports stellar Q2 results, eyes rare disease expansion

ANI Pharma delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and record EBITDA.
The company's focus on rare diseases and generics, along with a solid financial position, positions it well for future growth.
ANI Pharma faces challenges in maintaining growth momentum and navigating industry competition but has opportunities for expansion.

ANI Pharma reports record Q3 revenues, raises full-year guidance

ANI Pharmaceuticals (ANIP) delivered impressive Q3 results with record revenues and substantial growth in key segments. Despite market challenges, the company's strategic investments and raised guidance signal confidence in future performance and expansion.

ANI Pharmaceuticals reports record 2023 earnings, eyes growth opportunities

ANI Pharmaceuticals delivered a stellar performance in Q4 2023, achieving record revenue and profitability figures, driven by strong sales in key product segments.
While the company faces challenges in maintaining growth rates and navigating market dynamics, ANI Pharmaceuticals is well-positioned to capitalize on opportunities for expansion and innovation.
With a solid financial foundation, diverse product portfolio, and strategic growth outlook for 2024, ANI Pharmaceuticals remains poised for continued success and market leadership in the pharmaceutical industry.

ANI Pharma reports strong Q1 earnings, eyes Rare Disease growth

ANI Pharma's Q1 2024 performance reflects robust revenue growth across key segments, supported by strategic initiatives and a focus on innovation.
While facing challenges in R&D spending variability and supply tailwinds, the company remains well-positioned to capitalize on growth opportunities.
Opportunities lie in expanding the Rare Disease business, exploring new specialties for Cortrophin Gel, and pursuing strategic M&A for sustained growth.
ANI Pharma's prudent approach to capital deployment and confidence in growth through acquisitions underscore a promising outlook for future expansion.

ANI Pharma reports record revenues, announces Alimera acquisition for growth

ANI Pharma delivered a strong Q2 2024 performance with record revenues and significant growth in key product segments.
The proposed acquisition of Alimera Sciences signals ANI's strategic expansion into high-growth commercial products, enhancing its market position.
While facing integration challenges, ANI's raised guidance and focus on accretive EPS from the acquisition highlight a positive outlook for future growth.

ANI Pharmaceuticals (ANIP) reports record Q3 revenues and eyes rare disease growth in 2025

ANI Pharmaceuticals (ANIP) delivered a robust Q3 performance with record revenues and raised full-year guidance, driven by strong growth in Cortrophin Gel and generics business. The company's emphasis on rare diseases and new offerings positions it for continued growth in 2025. While challenges exist in the payer landscape and acquisition integration, ANIP's strategic focus on key specialties offers promising opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000 shares of its common stock were sold at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are $75 million, before deducting the underwriting discounts and commissions and offering expenses. In addition, ANI granted the underwriters a 30-day option to

ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to a

ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 3

ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

ABVC BioPharma

Moderna

Sanofi

Sorrento Therapeutics Inc

Biotech stocks to note as the coronavirus pandemic rages on across the globe.

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021

ANI Pharmaceuticals (NASDAQ: ANIP) recently announced that it recorded $52.1 million net revenues for its third quarter of 2021. However, this was roughly one million dollars less than what they reported in the same quarter of the previous fiscal year.

ANI Pharmaceuticals reports 3rd Quarter financial results as shares surges

The company reported positive third-quarter earnings, and the FDA granted approval for its generic version of Acthar Gel.

Here's Why Ani Pharmaceuticals Stock Is Rocketing Higher Today

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q3 2021 Results - Earnings Call Transcript

ANI (ANIP) delivered earnings and revenue surprises of 42.25% and 3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended September 30, 2021. Third Quarter and Recent Business Highlights: The U.S. Food and Drug Administration (FDA) approved the Company's supplemental new drug application (sNDA) for Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders

ANI Pharmaceuticals Reports Third Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protei

ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2021 financial results on Monday, November 1, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date     Monday, November 1, 2021 Time     8:30 a.m. ET Toll free (U.S.)     877-8

ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for

Atlas Air Worldwide

AeroCentury

Avis Budget Group

CF Industries Holdings

Choice Hotels Int.

People's United Financial

While the market rally this year has been incredible, worrying developments suggest investors should watch out for overbought stocks. The post 7 Overbought Stocks to Be Very Careful of Right Now appeared first on InvestorPlace.

7 Overbought Stocks to Be Very Careful of Right Now

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: Date:  Thursday, September 30, 2021 Time: 8:00 a.m. ET  Webcast Link:  https://wsw.com/webcast/cantor12/anip/2073680 The presentation will be webcast live at the aforementioned time, and archived for 30 days ther

ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI's Nebivolol Tablets is the generic version of the reference listed drug (“RLD”) Bystolic®. The current annual U.S. market for Bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion, according to IQVIA/IMS Health, a leading healthcare data and analytics provider. "The launch of Nebivolol

ANI Pharmaceuticals Announces Launch of Nebivolol Tablets

The FDA has accepted ANI Pharmaceuticals Inc's (NASDAQ: ANIP) supplemental marketing application for Purified Cortrophin Gel. The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.

ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company's supplemental New Drug Application (“sNDA”) for Purified Cortrophin® Gel (“Cortrophin Gel”) has been accepted by the U.S. Food and Drug Administration (“FDA”) for review. “FDA's acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript

ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021. Second Quarter and Recent Business Highlights: The Company refiled its supplemental new drug application (“sNDA”) for Cortrophin® Gel with the U.S. Food and Drug Administration (“FDA” or the “Agency”) on June 29, 2021; goal date is October 29, 2021; Acquisition of Novitium Pharma LLC (“Novi

ANI Pharmaceuticals Reports Second Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Friday, August 6, 2021 Time 8:30 a.m. ET Toll free (U.S.) 866-342-8591 Webcast

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company has re-filed its supplemental new drug application (“sNDA”) for Cortrophin® Gel with the U.S. Food and Drug Administration (“FDA”). “We are delighted to have re-filed our sNDA for Cortrophin Gel in the last week of June. ANI has carefully reviewed every communication from the FDA with our internal subject matter experts and enlisted additional expert advice from i

ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA

ANI's business growth rate could be on the cusp of a rapid acceleration.

A Low Valuation, High Growth Target: ANI Pharmaceuticals

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Raymond James Human Health Innovation Conference 2021 as follows: Date: Tuesday, June 22, 2021 Time: 12:00pm Eastern Time Webcast Link: https://kvgo.com/rj-health/ani-pharmaceuticals-inc-june-2021 The presentation will be webcast live at the aforementioned time, and archiv

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June 2, 2021, beginning at 10 a.m. Eastern Time. Stockholders can attend the virtual annual meeting via the internet at www.virtualshareholdermeeting.com/ANIP2021. Stockholders of record as of the close of business on April 26, 2021 will be eligible to vote their shares and submit questions electronic

News for ANI Pharma Stock (ANIP)